Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics is a commercial-stage clinical biopharmaceutical company specializing in the development and commercialization of antibody-based therapeutic products for the treatment of cancer. The company's mission is to become a world leader in developing safer and more effective antibody-based oncology treatments, particularly for pediatric cancers. Y-mAbs focuses on addressing unmet medical needs and has a broad product pipeline, including pivotal-stage product candidates against a range of targets.

Y-mAbs was founded in 2015 by Thomas Gad, a father of a high-risk neuroblastoma survivor, who envisioned helping other patients and families get access to effective cancer treatments. The company's key technologies include the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Y-mAbs leverages its extensive drug development capabilities and platform technology to create new types of bispecific antibodies, and is committed to advancing its product pipeline into certain adult cancer indications as well.

Y-mAbs Therapeutics is committed to helping employees maintain a healthy work-life balance. They offer benefits such as paid vacation and public holidays, as well as disability and health benefits. The company also provides employees with the opportunity to participate in professional development and growth opportunities. While specific work flexibility arrangements are not explicitly stated, the emphasis on work-life balance and benefits suggests a supportive environment for discussing individual needs and potentially accommodating flexible work schedules.

Y-mAbs Therapeutics is committed to helping employees maintain a work-life balance by providing paid vacation, public holidays, and other benefits such as disability and health benefits. These benefits are managed locally to comply with legislation.

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative, antibody-based therapies for cancer, with a particular focus on treating pediatric cancers. Driven by the desire to provide patients with the same life-changing treatments that helped the founder's daughter overcome neuroblastoma, the company aims to become a global leader in pediatric oncology, addressing unmet medical needs and improving the lives of patients. Their mission extends to developing and expanding their product pipeline for certain adult cancer indications, leveraging their extensive drug development capabilities and platform technology to create novel bispecific antibodies.

Y-mAbs Therapeutics promotes a culture focused on excellence in execution and a commitment to bringing new therapeutics to the market. They foster a collaborative and international team environment where employees are encouraged to be passionate about advancing the company's vision and have autonomy to drive innovation. They value integrity and respect, providing employees with opportunities for professional and personal growth.

Y-mAbs Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace. They believe that embracing different perspectives and backgrounds strengthens their organization and allows them to better serve their patients. While specific details on their approach are not readily available, their commitment to building a supportive and collaborative environment is evident in their efforts to attract and retain a talented workforce that reflects the diversity of the communities they serve.